Stock ARQT ARCUTIS BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Arcutis Biotherapeutics, Inc.

Equities

ARQT

US03969K1088

Real-time Estimate Cboe BZX
Other stock markets
 01:52:09 2024-06-07 pm EDT 		5-day change 1st Jan Change
7.24 USD -4.74% Intraday chart for Arcutis Biotherapeutics, Inc. -12.74% +125.85%
May. 28 Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion MT
May. 15 Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
GL
Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
AQ
Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
AQ
Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion
MT
Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating
MT
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday
MT
Sector Update: Health Care
MT
Mizuho Securities Adjusts Arcutis Biotherapeutics Price Target to $18 From $17, Maintains Buy Rating
MT
Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket
MT
Arcutis Biotherapeutics Q1 Loss Narrows, Revenue Increases; Shares Jump
MT
Transcript : Arcutis Biotherapeutics, Inc., Q1 2024 Earnings Call, May 14, 2024
Arcutis Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (ARQT) ARCUTIS BIOTHERAPEUTICS Posts Q1 Revenue $49.6M
MT
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
GL
Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
GL
Arcutis Biotherapeutics, Inc. Announces Journal of Clinical and Aesthetic Dermatology Publishes the Outcomes of a Comprehensive Evaluation by an Expert Dermatology
CI
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARQT Stock
  4. News Arcutis Biotherapeutics, Inc.